Trial RPCEC00000346
Publication Hernandez-Bernal, medRxiv, 2021
Primary outcome on the report: The main endpoints were: safety and proportion of subjects with seroconversion of anti-RBD IgG antibodies to SARS-CoV-2. The adverse events (type, duration, severity, outcome, and causality relationship) were carefully registered.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.